BiotechTube

Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peritoneal Neoplasms

Conditions

Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis

Trial Timeline

Sep 1, 2005 → Sep 1, 2008

NCT ID
NCT00332696

About Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + Placebo

Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + Placebo is a phase 2 stage product being developed by Novartis for Peritoneal Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00332696. Target conditions include Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis.

What happened to similar drugs?

3 of 7 similar drugs in Peritoneal Neoplasms were approved

Approved (3) Terminated (1) Active (4)
✅ertapenemMerckApproved
✅Extraneal (7.5% icodextrin) Peritoneal Dialysis SolutionBaxterApproved
✅Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solutionBaxterApproved
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
🔄PA21Kissei PharmaceuticalPhase 3
🔄Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )SanofiPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00332696Phase 2Completed

Competing Products

20 competing products in Peritoneal Neoplasms

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
32
MCY-M11 + CyclophosphamideMaxCytePhase 1
11
R744 + R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
AbemaciclibEli LillyPhase 1
36
M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab)AbbViePhase 1/2
32
Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLDAstraZenecaPhase 2
35
Tremelimumab + OlaparibAstraZenecaPhase 1
21
ertapenemMerckApproved
43
PA21Kissei PharmaceuticalPhase 3
40
PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2PfizerPhase 1/2
24
Bevacizumab + Nivolumab + RucaparibBristol Myers SquibbPhase 2
39
IniparibSanofiPhase 2
35
Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )SanofiPhase 3
40
nanoliposomal irinotecanIpsenPhase 1
26
Extraneal (7.5% icodextrin) Peritoneal Dialysis SolutionBaxterApproved
32
Anti-Adhesion ProductBaxterPhase 2
32
PioglitazoneBaxterPre-clinical
23
Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solutionBaxterApproved
47
RadspherinOncoinventPhase 2
32